This Month in JNM

November 1, 2018

Network-linked neurodegenerative patterns: Drzezga looks at growing evidence that neurodegenerative disorders are characterized by the spread of specific molecular neuropathologic features along neuronal brain networks and examines associated imaging techniques, network overlaps, and potential causative relationships. Page 1645

Interventional oncology and the liver: Voutsinas and colleagues provide an educational overview of indications for 90Y radioembolization, the roles of preprocedural angiography and 99mTc-macroaggregated albumin scans, different dosing techniques, types of microspheres, and potential complications. Page 1649

43,44Sc, 52Mn, and 45Ti: Chaple and Lapi describe the characteristics of these emerging metal radionuclides and their potential as new PET agents. Page 1655

PET and cerebral small vessel disease: Heiss details the advantages of functional information from the addition of 18F-FDG PET to current diagnostic imaging in cerebral small vessel disease, including differentiation of vascular and degenerative cognitive impairment. Page 1660

NaF and PSMA PET/CT: Harmon and colleagues compare the diagnostic performance of 18F-DCFBC, a first-generation prostate-specific membrane antigen (PSMA)–targeted agent, and 18F-NaF, a sensitive marker of osteoblastic activity, in PET/CT imaging in patients with metastatic prostate cancer. Page 1665

11C-Choline dynamic PET in PCa: Grkovski and colleagues investigate the value of pharmacokinetic modeling for quantifying 11C-choline uptake in patients with clinically suspected recurrent prostate cancer. Page 1672

ανβ6 integrin–binding peptides: Roesch and colleagues analyze the affinity and specificity of 5 native ανβ6 integrin–specific binders in comparison to SFITGv6, a novel potential tracer for imaging and targeted therapy of ανβ6 integrin–positive carcinomas. Page 1679

Featured Article of the Month:
c-Met–targeted imaging:
Han and colleagues report on preclinical studies with 99mTc-HYNIC-cMBP, a c-Met–binding peptide radiotracer for SPECT imaging, with promise for clinical selection and monitoring of non–small cell lung cancer for c-Met–responsive therapy. Page 1686

90Y-DOTATOC dosimetry: Menda and colleagues describe a dosimetric method for 90Y-DOTATOC using 90Y-DOTATOC PET/CT and bremsstrahlung SPECT/CT and determine whether dosimetry-based administered activities differ significantly from standard doses. Page 1692

PRRT with 177Lu-DOTA-EB-TATE: Zhang and colleagues present the results of a first-in-human study exploring the safety and dosimetry of this long-acting radiolabeled somatostatin analog with promise for peptide receptor radionuclide therapy for neuroendocrine tumors. Page 1699

Radiopharmaceutical therapy now: Divgi offers perspective on the importance of broad clinical rigor in radiopharmaceutical clinical practice and previews an article in this issue of JNM on 131I-MIBG for metastatic neuroendocrine tumors. Page 1706

Survival after 131I-MIBG therapy: Kane and colleagues provide a retrospective analysis identifying predictors of survival in patients with MIBG–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumors treated with 131I-MIBG therapy. Page 1708

Featured Clinical Investigation Article:
Ga-PSMA-11 PET/CT for RT planning:
Calais and colleagues determine how often definitive radiation treatment planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT–defined disease and assess the potential impact of 68Ga-PSMA-11 PET/CT on definitive planning. Page 1714

PET in Huntington disease: Bertoglio and colleagues use 11C-ABP688 PET imaging to longitudinally characterize in vivo changes in metabotropic glutamate receptor 5 in a mouse model of Huntington disease. Page 1722

123I-MIBG scintigraphy and wearing-off in PD: Lee and colleagues investigate whether cardiac sympathetic denervation increases the risk of the early wearing-off phenomenon in Parkinson disease. Page 1728

PET/CT in cyst infection in ADPKD: Pijl and colleagues assess the value of 18F-FDG PET/CT for diagnosing renal or hepatic cyst infection in patients with autosomal dominant polycystic kidney disease. Page 1734

Cost and bone SPECT/CT in TKA: Wyngaert and colleagues quantify the economic value of bone SPECT/CT and CT or metal artifact reduction–sequence MR imaging for diagnostic assessment of recurrent moderate-to-severe pain after total knee arthroplasty. Page 1742

124I-DPA-713 PET/CT clinical studies: Foss and colleagues detail biodistribution and radiation dosimetry of this radioligand for the 18-kDa translocator protein in healthy individuals and discuss its potential in imaging of macrophage-associated inflammation. Page 1751

Multispectral surgical guidance: Meershoek and colleagues describe preclinical studies with a multispectral fluorescence guidance approach that enables discrimination between prostate-draining and lower-limb–draining lymph nodes in prostate cancer surgery. Page 1757

Rebinner with rigid motion correction: Reilhac and colleagues implement an accurate list-mode–based rigid motion correction method for PET data acquired with the mMR synchronous PET/MR scanner and optimize correction for 11C-Pittsburgh compound B scans. Page 1761

PET spatial resolution: Lodge and colleagues introduce a technique that can be used to measure the spatial resolution that can be expected with clinical PET protocols, potentially providing more relevant estimates than are typically obtained with established experimental procedures. Page 1768